|
1
|
Azuma H, Banno K and Yoshimura T:
Pharmacological properties of N-(3′,4′-dimethoxycinnamoyl)
anthranilic acid (N-5′), a new anti-atopic agent. Br J Pharmacol.
58:483–488. 1976.
|
|
2
|
Taniguchi S, Yorifuji T and Hamada T:
Treatment of linear localized scleroderma with the anti-allergic
drug, tranilast. Clin Exp Dermatol. 19:391–393. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yamada H, Ide A, Sugiura M and Tajima S:
Treatment of cutaneous sarcoidosis with tranilast. J Dermatol.
22:149–152. 1995.PubMed/NCBI
|
|
4
|
Yamada H, Tajima S, Nishikawa T, Murad S
and Pinnell SR: Tranilast, a selective inhibitor of collagen
synthesis in human skin fibroblasts. J Biochem. 116:892–897.
1994.PubMed/NCBI
|
|
5
|
Suzawa H, Kikuchi S, Ichikawa K and Koda
A: Inhibitory action of tranilast, an anti-allergic drug, on the
release of cytokines and PGE2 from human monocytes-macrophages. Jpn
J Pharmacol. 60:85–90. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Adachi S, Maruyama T, Kondo T, Todoroki T
and Fukao K: The prevention of postoperative intraperitoneal
adhesions by tranilast: N-(3′,4′-dimethoxycinnamoyl)anthranilic
acid. Surg Today. 29:51–54. 1999.PubMed/NCBI
|
|
7
|
Nakamura K, Irie H, Inoue M, Mitani H,
Sunami H and Sano S: Factors affecting hypertrophic scar
development in median sternotomy incisions for congenital cardiac
surgery. J Am Coll Surg. 185:218–223. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Watanabe S, Matsuda A, Suzuki Y, et al:
Inhibitory mechanism of tranilast in human coronary artery smooth
muscle cells proliferation, due to blockade of PDGF-BB-receptors.
Br J Pharmacol. 130:307–314. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takahashi A, Taniguchi T, Ishikawa Y and
Yokoyama M: Tranilast inhibits vascular smooth muscle cell growth
and intimal hyperplasia by induction of p21(waf1/cip1/sdi1) and
p53. Circ Res. 84:543–550. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tamai H1, Katoh O, Suzuki S, et al: Impact
of tranilast on restenosis after coronary angioplasty: tranilast
restenosis following angioplasty trial (TREAT). Am Heart J.
138:968–75. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tamai H, Katoh K, Yamaguchi T, et al: The
impact of tranilast on restenosis after coronary angioplasty: the
Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2).
Am Heart J. 143:506–513. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Holmes DR Jr, Savage M, LaBlanche JM, et
al: Results of Prevention of REStenosis with Tranilast and its
Outcomes (PRESTO) trial. Circulation. 106:1243–1250. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Umemura K, Kikuchi S, Suzuki Y and
Nakashima M: Inhibitory effect of tranilast on hypertrophic
collagen production in the spontaneously hypertensive rat heart.
Jpn J Pharmacol. 78:161–167. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kagitani S, Ueno H, Hirade S, Takahashi T,
Takata M and Inoue H: Tranilast attenuates myocardial fibrosis in
association with suppression of monocyte/macrophage infiltration in
DOCA/salt hypertensive rats. J Hypertens. 22:1007–1015. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bujak M and Frangogiannis NG: The role of
TGF-beta signaling in myocardial infarction and cardiac remodeling.
Cardiovasc Res. 74:184–195. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dewald O, Ren G, Duerr GD, et al: Of mice
and dogs: species-specific differences in the inflammatory response
following myocardial infarction. Am J Pathol. 164:665–677. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cohn JN, Ferrari R and Sharpe N: Cardiac
remodeling - concepts and clinical implications: a consensus paper
from an international forum on cardiac remodeling. Behalf of an
International Forum on Cardiac Remodeling. J Am Coll Cardiol.
35:569–582. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ikeuchi M, Tsutsui H, Shiomi T, et al:
Inhibition of TGF-beta signaling exacerbates early cardiac
dysfunction but prevents late remodeling after infarction.
Cardiovasc Res. 64:526–535. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
See F, Watanabe M, Kompa AR, et al: Early
and delayed tranilast treatment reduces pathological fibrosis
following myocardial infarction. Heart Lung Circ.
Sept.14–2012.(Epub ahead of print).
|
|
20
|
Jung C, Gonon AT, Sjöquist PO, Lundberg JO
and Pernow J: Arginase inhibition mediates cardioprotection during
ischaemia-reperfusion. Cardiovasc Res. 85:147–154. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pfeffer MA, Pfeffer JM, Fishbein MC,
Fletcher PJ, Spadaro J, Kloner RA and Braunwald E: Myocardial
infarct size and ventricular function in rats. Circ Res.
44:503–512. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fletcher PJ, Pfeffer JM, Pfeffer MA and
Braunwald E: Left ventricular diastolic pressure-volume relations
in rats with healed myocardial infarction. Effects on systolic
function. Circ Res. 49:618–626. 1981.PubMed/NCBI
|
|
23
|
Carluccio E, Biagioli P, Alunni G, et al:
Patients with hibernating myocardium show altered left ventricular
volumes and shape, which revert after revascularization: evidence
that dyssynergy might directly induce cardiac remodeling. J Am Coll
Cardiol. 47:969–977. 2006.
|
|
24
|
Bax JJ, Schinkel AF, Boersma E, et al:
Extensive left ventricular remodeling does not allow viable
myocardium to improve in left ventricular ejection fraction after
revascularization and is associated with worse long-term prognosis.
Circulation. 110:II18–II22. 2004.PubMed/NCBI
|
|
25
|
Senior R, Lahiri A and Kaul S: Effect of
revascularization on left ventricular remodeling in patients with
heart failure from severe chronic ischemic left ventricular
dysfunction. Am J Cardiol. 88:624–629. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brown EJ Jr, Kloner RA, Schoen FJ,
Hammerman H, Hale S and Braunwald E: Scar thinning due to ibuprofen
administration after experimental myocardial infarction. Am J
Cardiol. 51:877–883. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bulkley BH and Roberts WC: Steroid therapy
during acute myocardial infarction. A cause of delayed healing and
of ventricular aneurysm. Am J Med. 56:244–250. 1974. View Article : Google Scholar
|
|
28
|
Weber KT, Sun Y and Cleutjens JP:
Structural remodeling of the infarcted rat heart. EXS. 76:489–499.
1996.PubMed/NCBI
|
|
29
|
Betge S, Lutz K, Roskos M and Figulla HR:
Oral treatment with probucol in a pharmacological dose has no
beneficial effects on mortality in chronic ischemic heart failure
after large myocardial infarction in rats. Eur J Pharmacol.
558:119–127. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Karatas A, Hegner B, de Windt LJ, et al:
Deoxycorticosterone acetate-salt mice exhibit blood
pressure-independent sexual dimorphism. Hypertension. 51:1177–1183.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tyagi P, Tyagi V, Yoshimura N, et al:
Gender-based reciprocal expression of transforming growth
factor-beta1 and the inducible nitric oxide synthase in a rat model
of cyclophosphamide-induced cystitis. J Inflamm (Lond). 6:232009.
View Article : Google Scholar
|
